- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, July 24, 2020
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care® (AJMC®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS
January 6th 2025A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Read More
Functional Precision Medicine Tool Predicts Treatment Response in AML
January 6th 2025A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
Read More
